A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Part of paid clinical trials in Escondido, California.
- Sponsor
- AstraZeneca
- Study ID
- NCT07776509
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Obesity or Overweight
- Weight-Related Comorbidity
- With/Without Diabetes Mellitus, Type 2
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- AZD6234 — DRUGIMP injected subcutaneously, once a week.
- Placebo — DRUGPlacebo matching IMP dose injected subcutaneously, once a week.
Study Details
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
Key Dates
- First listed
- Aug 20, 2026
- Start date
- Aug 21, 2026
- Status verified
- Aug 2026
- Primary completion
- Aug 9, 2028
- Completion
- Aug 9, 2028
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: AZD6234AZD6234
- Placebo Comparator: PlaceboMatching placebo
Primary Outcome Measure
Percent change in body weight from baseline at 68 weeks of treatment [ Time Frame: 68 weeks ]
Central Contacts
- AstraZeneca Clinical Study Information Center1-877-240-9479
Locations (23)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Escondido | California | 92025 | - |
| Research Site | Lincoln | California | 95648 | - |
| Research Site | Walnut Creek | California | 94598 | - |
| Research Site | Fleming Island | Florida | 32003 | - |
| Research Site | Jacksonville | Florida | 32205 | - |
| Research Site | Stockbridge | Georgia | 30281 | - |
| Research Site | Woodstock | Georgia | 30189 | - |
| Research Site | Champaign | Illinois | 61822 | - |
| Research Site | Chicago | Illinois | 60640 | - |
| Research Site | Beltsville | Maryland | 20705 | - |
| Research Site | Oxon Hill | Maryland | 20745 | - |
| Research Site | Kansas City | Missouri | 64111 | - |
| Research Site | Las Vegas | Nevada | 89101 | - |
| Research Site | Somerset | New Jersey | 08873 | - |
| Research Site | Statesville | North Carolina | 28625 | - |
| Research Site | Fargo | North Dakota | 58104 | - |
| Research Site | Columbus | Ohio | 43215 | - |
| Research Site | Portland | Oregon | 97202 | - |
| Research Site | Smithfield | Pennsylvania | 15478 | - |
| Research Site | Franklin | Tennessee | 37067 | - |
| Research Site | Houston | Texas | 77043 | - |
| Research Site | Manassas | Virginia | 20110 | - |
| Research Site | Renton | Washington | 98057 | - |
Related Studies
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyPHASE3 · Recruiting · Eli Lilly and Company · Dothan, Alabama
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightPHASE3 · Recruiting · Eli Lilly and Company · Dothan, Alabama
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesPHASE3 · Recruiting · Hoffmann-La Roche · Anniston, Alabama
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesPHASE3 · Recruiting · Hoffmann-La Roche · Guntersville, Alabama